Dr. Mann on Differences Between Treatments for Prostate Cancer

Mark J. Mann, MD
Published: Friday, Mar 23, 2018



Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the differences between treatment options for patients with prostate cancer subtypes.

For patients with nonmetastatic castration-sensitive prostate cancer, treatment options have been standardized for a long time with androgen deprivation therapy. However, in nonmetastatic castration-resistant prostate cancer (CRPC), studies have not shown many effective treatment options until recently, says Mann. Studies have investigated denosumab (Xgeva), which did not show any efficacy, and zoledronic acid, which showed a similar response.

With newer imaging modalities, a question is whether a patient is really nonmetastatic, explains Mann. Gallium-68 PET/CT scans identify metastatic disease that was previously not visible. That is likely to change the nonmetastatic castration-sensitive and nonmetastatic CRPC treatment landscape. According to Mann, physicians should consider using drugs from the STAMPEDE and LATITUDE trials.
 


Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the differences between treatment options for patients with prostate cancer subtypes.

For patients with nonmetastatic castration-sensitive prostate cancer, treatment options have been standardized for a long time with androgen deprivation therapy. However, in nonmetastatic castration-resistant prostate cancer (CRPC), studies have not shown many effective treatment options until recently, says Mann. Studies have investigated denosumab (Xgeva), which did not show any efficacy, and zoledronic acid, which showed a similar response.

With newer imaging modalities, a question is whether a patient is really nonmetastatic, explains Mann. Gallium-68 PET/CT scans identify metastatic disease that was previously not visible. That is likely to change the nonmetastatic castration-sensitive and nonmetastatic CRPC treatment landscape. According to Mann, physicians should consider using drugs from the STAMPEDE and LATITUDE trials.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x